STERIS’ (TSE:STE – Get Rating) – Equities researchers at Raymond James increased their FY2022 earnings estimates for STERIS’ in a research note issued to investors on Thursday, September 15th. Raymond James analyst A. Bradford now expects that the company will earn $1.15 per share for the year, up from their previous estimate of $1.01. Raymond James also issued estimates for STERIS’’s FY2023 earnings at $1.11 EPS.
STERIS’ Price Performance
STERIS’ (TSE:STE – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The company reported C$0.54 earnings per share for the quarter, topping the consensus estimate of C$0.20 by C$0.34. The company had revenue of C$273.00 million during the quarter, compared to the consensus estimate of C$252.87 million.
STERIS’ Company Profile
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.